The Division of Genitourinary Pathology at NewYork-Presbyterian/Weill Cornell Medicine features the proficiency of full-time pathologists with dedicated expertise. Our pathologists have completed fellowship training at the top institutions around the country and are authorities in the field of genitourinary pathology, contributing numerous scientific publications to peer-reviewed journals.
Our team offers a wide spectrum of pathologic services and evaluates more than 2,900 specimens each year from the kidney, prostate, bladder, and testis. (Non-neoplastic kidney specimens are assessed by the Division of Renal Pathology). We offer complete diagnostic services with ancillary tests, including comprehensive immunohistochemistry panels and fluorescence in situ hybridization (FISH). Weill Cornell is one of the nation's leading centers for robotic-assisted prostatectomy and cystectomy, affording our genitourinary pathologists with a large number of prostate and bladder specimens for review and further building their expertise.
NewYork-Presbyterian/Weill Cornell's genitourinary pathologists also conduct research to better understand the pathophysiology of urologic diseases. The team of Dr. Mark A. Rubin comprises one of the largest groups in prostate cancer research, leading the translation of novel basic science discoveries in genomics and epigenomics to the clinic. Dr. Rubin’s expertise in prostate cancer genomics — in collaboration with other institutions (University of Michigan and the Broad Institute of Harvard/MIT in Cambridge, Massachusetts) — has led to breakthrough discoveries, including the identification and roles of ETS fusion genes and SPOP mutations in prostate cancer, and the potential roles of AURKA (Aurora kinase A) and N-myc genes in neuroendocrine prostate cancer (a lethal form of the disease). Among the genomic research accomplishments of Dr. Rubin and other Weill Cornell faculty are the characterization of the mutational spectrum of prostate cancer and identification of genetic targets for the development of clinical therapies. Dr. Rubin’s group also joins a prestigious list of researchers who have received funding from Stand Up to Cancer, in collaboration with the Prostate Cancer Foundation, awarded to recognize excellence in prostate cancer research.
Dr. Rubin also leads the Institute for Precision Medicine at NewYork-Presbyterian/Weill Cornell. This cutting-edge translational medicine research hub will explore the new frontier of precision medicine and will offer optimal targeted, individualized treatment based on the genetic profile of each patient's tumor. The Institute's genomic research discoveries will help generate novel personalized medical therapies to be assessed in clinical trials, while also building a comprehensive biobank to improve research and patient care.
In addition to patient care and research, the genitourinary pathologists are committed to educating residents and fellows. Pathology residents learn about genitourinary pathology, and Urology residents who are pursuing research interact with the Department of Pathology, especially those who are conducting prostate and bladder cancer research. A very competitive one-year Genitourinary Pathology Fellowship is offered by the Department of Pathology and Laboratory Medicine, and Translational Research Fellowships in Genitourinary Pathology attract physicians from all over the world.